Advanced Enzyme Technologies Gelecekteki Büyüme
Future kriter kontrolleri 2/6
Advanced Enzyme Technologies kazanç ve gelirin sırasıyla yıllık 10% ve 14.5% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 10.2% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 12.2% olacağı tahmin edilmektedir.
Anahtar bilgiler
10.0%
Kazanç büyüme oranı
10.16%
EPS büyüme oranı
| Chemicals kazanç büyümesi | 18.3% |
| Gelir büyüme oranı | 14.5% |
| Gelecekteki özkaynak getirisi | 12.20% |
| Analist kapsamı | Low |
| Son güncelleme | 05 Feb 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Analiz Makalesi • Jun 30
If EPS Growth Is Important To You, Advanced Enzyme Technologies (NSE:ADVENZYMES) Presents An Opportunity
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Anlatı Güncellemesi • Jun 18
ADVENZYMES: Stable Case Balances Model Assumptions And Upcoming Dividend Decisions
Analysts have kept their ₹370 price target on Advanced Enzyme Technologies unchanged, citing slightly adjusted assumptions for discount rate, revenue growth, profit margin and future P/E that, in their view, broadly offset each other in the valuation model. Analyst Commentary Recent commentary on Advanced Enzyme Technologies highlights a mix of optimism about the company’s positioning and caution around execution and valuation assumptions, which feeds into how analysts are thinking about the ₹370 target.Anlatı Güncellemesi • Jun 01
ADVENZYMES: Steady Cash Assumptions And Upcoming Board Decisions Will Shape Returns
Narrative update on Advanced Enzyme Technologies The analyst price target for Advanced Enzyme Technologies is held steady at ₹370, as analysts point to only very small adjustments in assumptions for discount rate, revenue growth, profit margin and forward P/E after reviewing recent research on comparable companies. Analyst Commentary Recent Street research on other mid-cap service companies has given analysts a reference point as they revisit models for Advanced Enzyme Technologies, even though those reports focus on a different stock.Anlatı Güncellemesi • May 12
ADVENZYMES: Stable Margins And Refined Assumptions Will Guide Future Returns
Analysts kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, citing modest adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions rather than any change in their core outlook. Analyst Commentary Analysts keeping fair value at ₹370 are focusing on how well Advanced Enzyme Technologies can execute on its current plan rather than changing their fundamental view of the stock.Anlatı Güncellemesi • Apr 19
ADVENZYMES: Steady Risk And Margins Will Support Future Upside
Analysts have kept their fair value estimate for Advanced Enzyme Technologies steady at ₹370. They cited updated assumptions around the discount rate, growth, margins and future P/E that reflect fine tuning of their models rather than a change in overall conviction.Anlatı Güncellemesi • Apr 05
ADVENZYMES: Steady Assumptions And Risk Profile Will Support Future Upside
Analysts have kept the fair value estimate for Advanced Enzyme Technologies steady at ₹370, with only small adjustments to the discount rate, growth, margin and future P/E assumptions informing this unchanged price target. Analyst Commentary Bullish Takeaways Bullish analysts see support for the ₹370 fair value estimate from the decision to keep key model assumptions, such as growth and margins, broadly consistent rather than revising them sharply.Anlatı Güncellemesi • Mar 21
ADVENZYMES: Refined Risk Assumptions And Stable Outlook Will Support Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370, making small changes to assumptions such as a slightly lower discount rate and marginally adjusted long-term growth and P/E inputs after revisiting their models. Analyst Commentary Bullish Takeaways Bullish analysts see the reaffirmed fair value of ₹370 as supported by refreshed assumptions, suggesting that the refined discount rate and long term inputs still back the existing valuation framework for Advanced Enzyme Technologies.Anlatı Güncellemesi • Mar 06
ADVENZYMES: Free Cash Flow Momentum And Cleaner Portfolio Will Drive Upside
Analysts have maintained their fair value estimate for Advanced Enzyme Technologies at ₹370.0 per share, while slightly adjusting assumptions on discount rate, growth, margins and future P/E to reflect updated free cash flow trends and a cleaner portfolio. They expect these factors to support improvement in the second half.Anlatı Güncellemesi • Feb 20
ADVENZYMES: Stable Assumptions And Future P/E Reset Will Drive Upside
Analysts have kept their price target for Advanced Enzyme Technologies steady at ₹370, citing largely unchanged assumptions around the discount rate, revenue growth, profit margin and future P/E in their updated models. What's in the News A board meeting is scheduled on January 31, 2026 to consider and approve unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Anlatı Güncellemesi • Feb 05
ADVENZYMES: Future P/E Reset Will Signal Upside Potential For Shares
Analysts have trimmed their fair value estimate for Advanced Enzyme Technologies from ₹440 to ₹370, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple. What's in the News Board meeting scheduled for January 31, 2026, to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Analiz Makalesi • Jan 31
Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price Not Quite Adding Up
There wouldn't be many who think Advanced Enzyme Technologies Limited's ( NSE:ADVENZYMES ) price-to-earnings (or "P/E...Yeni Anlatı • Aug 17
Preventive Health And Green Chemistry Will Expand Future Markets
Key Takeaways Expansion into health, wellness, and sustainable enzymatic solutions, along with new B2C initiatives, positions for growth and improved margins as consumer demand rises. International diversification, R&D investment, and increased capacity utilization support long-term product differentiation, earnings stability, and operating leverage.Analiz Makalesi • Aug 04
Here's What's Concerning About Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Analiz Makalesi • Jun 27
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Dividend Will Be ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analiz Makalesi • Jun 12
Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Due To Pay A Dividend Of ₹1.20
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.20...Analiz Makalesi • Mar 25
Is Advanced Enzyme Technologies (NSE:ADVENZYMES) A Risky Investment?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Analiz Makalesi • Aug 20
After Leaping 26% Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Are Not Flying Under The Radar
Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) shareholders have had their patience rewarded with a 26% share...Analiz Makalesi • Jul 19
We Think Shareholders Are Less Likely To Approve A Pay Rise For Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) CEO For Now
Key Insights Advanced Enzyme Technologies' Annual General Meeting to take place on 25th of July Salary of ₹6.69m is...Analiz Makalesi • Jul 13
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
The board of Advanced Enzyme Technologies Limited ( NSE:ADVENZYMES ) has announced that it will pay a dividend of ₹1.00...Analiz Makalesi • Apr 08
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analiz Makalesi • Sep 23
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Finding a business that has the potential to grow substantially is not easy, but it is possible if we look at a few key...Analiz Makalesi • Feb 03
Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? In a perfect world...Analiz Makalesi • Aug 11
Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Did you know there are some financial metrics that can provide clues of a potential multi-bagger? Amongst other things...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 3/31/2028 | 9,970 | 2,053 | 733 | 1,678 | 1 |
| 3/31/2027 | 8,535 | 1,729 | 876 | 1,441 | 1 |
| 3/31/2026 | 7,458 | 1,687 | 1,044 | 1,568 | N/A |
| 12/31/2025 | 7,096 | 1,522 | N/A | N/A | N/A |
| 9/30/2025 | 7,067 | 1,474 | 1,323 | 1,643 | N/A |
| 6/30/2025 | 6,683 | 1,369 | N/A | N/A | N/A |
| 3/31/2025 | 6,369 | 1,311 | 1,077 | 1,425 | N/A |
| 12/31/2024 | 6,275 | 1,329 | N/A | N/A | N/A |
| 9/30/2024 | 6,194 | 1,371 | 904 | 1,422 | N/A |
| 6/30/2024 | 6,311 | 1,386 | N/A | N/A | N/A |
| 3/31/2024 | 6,239 | 1,333 | 941 | 1,414 | N/A |
| 12/31/2023 | 6,048 | 1,371 | N/A | N/A | N/A |
| 9/30/2023 | 5,859 | 1,248 | 965 | 1,327 | N/A |
| 6/30/2023 | 5,668 | 1,166 | N/A | N/A | N/A |
| 3/31/2023 | 5,406 | 1,056 | 1,022 | 1,404 | N/A |
| 12/31/2022 | 5,337 | 979 | N/A | N/A | N/A |
| 9/30/2022 | 5,251 | 960 | 806 | 1,164 | N/A |
| 6/30/2022 | 5,135 | 995 | N/A | N/A | N/A |
| 3/31/2022 | 5,294 | 1,196 | 941 | 1,223 | N/A |
| 12/31/2021 | 5,309 | 1,268 | N/A | N/A | N/A |
| 9/30/2021 | 5,350 | 1,424 | 1,127 | 1,374 | N/A |
| 6/30/2021 | 5,325 | 1,500 | N/A | N/A | N/A |
| 3/31/2021 | 5,018 | 1,459 | 1,434 | 1,630 | N/A |
| 12/31/2020 | 4,820 | 1,459 | N/A | N/A | N/A |
| 9/30/2020 | 4,569 | 1,364 | 978 | 1,472 | N/A |
| 6/30/2020 | 4,481 | 1,301 | N/A | N/A | N/A |
| 3/31/2020 | 4,440 | 1,293 | 904 | 1,409 | N/A |
| 12/31/2019 | 4,480 | 1,302 | N/A | N/A | N/A |
| 9/30/2019 | 4,366 | 1,210 | N/A | 1,276 | N/A |
| 6/30/2019 | 4,288 | 1,148 | N/A | N/A | N/A |
| 3/31/2019 | 4,220 | 1,111 | N/A | 1,286 | N/A |
| 12/31/2018 | 4,194 | 1,061 | N/A | N/A | N/A |
| 9/30/2018 | 4,261 | 1,068 | N/A | N/A | N/A |
| 6/30/2018 | 4,199 | 1,039 | N/A | N/A | N/A |
| 3/31/2018 | 3,918 | 901 | N/A | 1,160 | N/A |
| 12/31/2017 | 3,660 | 837 | N/A | N/A | N/A |
| 9/30/2017 | 3,213 | 725 | N/A | N/A | N/A |
| 6/30/2017 | 3,127 | 793 | N/A | N/A | N/A |
| 3/31/2017 | 3,290 | 915 | N/A | 1,074 | N/A |
| 12/31/2016 | 3,260 | 942 | N/A | N/A | N/A |
| 9/30/2016 | 3,404 | 998 | N/A | N/A | N/A |
| 6/30/2016 | 3,184 | 854 | N/A | N/A | N/A |
| 3/31/2016 | 2,938 | 759 | N/A | 934 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ADVENZYMES 'nin tahmini kazanç büyümesi (yıllık 10% ) tasarruf oranının ( 6.9% ) üzerindedir.
Kazançlar ve Piyasa: ADVENZYMES şirketinin kazançlarının (yıllık 10% ) Indian pazarından (yıllık 16.3% ) daha yavaş büyümesi öngörülüyor.
Yüksek Büyüme Kazançları: ADVENZYMES şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.
Gelir ve Pazar: ADVENZYMES şirketinin gelirinin (yıllık 14.5% ) Indian pazarından (yıllık 11% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ADVENZYMES şirketinin gelirinin (yıllık 14.5% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ADVENZYMES 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 12.2 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/06 15:21 |
| Gün Sonu Hisse Fiyatı | 2026/07/06 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2026/03/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Advanced Enzyme Technologies Limited 4 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Nandan Chakraborty | Axis Capital Limited |
| Abhishek Navalgund | Centrum Broking Limited |
| null null | DBS Bank Ltd |